IL-17 antibodies gain momentum Nature.com In pursuit are Amgen and Eli Lilly and Company, which also have IL-17-targeting monoclonal antibodies (mAbs) in Phase III development for psoriasis. Amgen's brodalumab and Lilly's ixekizumab both achieved similar efficacy as secukinumab in Phase II ... |
